The company's revenue (GAAP) reached $21.2 million, up from $15.3 million in Q2 2024, outpacing the analyst consensus of $20.45 million (GAAP). Earnings per share (EPS, GAAP) were $(0.38), also better ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ...

VistaGen Therapeutics (NASDAQ:VTGN) is scheduled to announce Q1 earnings results on Thursday, August 7th, after market close. The consensus EPS Estimate is -$0.44 (-25.7% Y/Y) and the consensus ...